Dermata Therapeutics (DRMA) Shares Outstanding (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Shares Outstanding (Entity) of $4.0 million for Q1 2026, up 680.29% year-over-year from $515470.0 in Q1 2025, and up 334.27% quarter-over-quarter from $926192.0 in Q4 2025.
Dermata Therapeutics (DRMA) Shares Outstanding (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $4.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 680.29% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 680.29% YoY), while the FY2025 annual figure was $926192.0, up 505.46% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $4.0 million, up from $926192.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $4.0 million in Q1 2026, with the low at $3470.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $44400.0 (2024), against an average of $462093.1.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) jumped 89.42% in 2023, then jumped 1381.93% in 2025.
- Dermata Therapeutics' Shares Outstanding (Entity) stood at $5134.0 in 2022, then surged by 279.76% to $19497.0 in 2023, then soared by 684.6% to $152974.0 in 2024, then soared by 505.46% to $926192.0 in 2025, then soared by 334.27% to $4.0 million in 2026.
- Business Quant data shows DRMA's Shares Outstanding (Entity) at $4.0 million in Q1 2026, $926192.0 in Q4 2025, and $844457.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | 926,192.00 |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 515,470.00 |
| Dec 31, 2024 | 152,974.00 |
| Sep 30, 2024 | 155,468.00 |
| Jun 30, 2024 | 67,657.00 |
| Mar 31, 2024 | 44,408.00 |
| Dec 31, 2023 | 19,497.00 |
| Sep 30, 2023 | 21,261.00 |
| Jun 30, 2023 | 18,033.00 |
| Mar 31, 2023 | 6,573.00 |
| Dec 31, 2022 | 4,605.00 |
| Sep 30, 2022 | 5,115.00 |
| Jun 30, 2022 | 4,665.00 |
| Mar 31, 2022 | 3,480.00 |
| Dec 31, 2021 | 1,793.00 |
| Sep 30, 2021 | 2,075.00 |
| Jun 30, 2021 | 796.00 |